目的:探讨前列地尔联合鼠神经生长因子对2型糖尿病神经病变患者血清同型半胱氨酸(Hcy)、超敏C反应蛋白(hs-CRP)及抗氧化能力的影响。方法:选取2016年4月至2019年4月太钢总医院内分泌科收治的128例2型糖尿病神经病变患者，男75例，女53例，年龄(61.13±8.92)岁，年龄范围为34～78岁，根据用药方法的不同将患者分成前列地尔组(n n＝37)、鼠神经生长因子组(n n＝42)及联合治疗组(n n＝49)，对三组患者进行多伦多周围神经病变评分(TCSS)和视觉模拟评分(VAS)；使用全功能诱发电位仪检测患者正中神经、胫骨神经及腓肠神经的感觉(SCV)和运动电位(MCV)；采用酶联免疫吸附试验检测Hcy、hs-CRP及抗氧化指标丙二醛、超氧化物歧化酶(SOD)水平。n 结果:治疗后，联合治疗组TCSS、VAS[(3.15±0.84)分、(1.35±1.09)分]显著低于前列地尔组[(7.05±1.13)分、(2.13±0.42)分]和鼠神经生长因子组[(6.82±1.27)分、(2.05±0.36)分]；联合治疗组正中神经、胫骨神经、下肢腓肠神经中SCV[(49.31±4.15)m/s、(49.15±4.03)m/s、(55.09±4.28)m/s]、MCV[(57.84±4.75)m/s、(47.85±4.13)m/s、(48.29±4.35)m/s]均高于前列地尔组[(45.81±3.71)m/s、(45.95±3.88)m/s、(44.07±3.69)m/s、(48.08±4.58)m/s、(39.14±3.04)m/s、(41.04±3.88)m/s]和鼠神经生长因子组[(44.92±3.59)m/s、(48.08±3.92)m/s、(49.27±4.12)m/s、(54.92±4.61)m/s、(43.55±3.92)m/s、(44.27±3.69)m/s]；联合治疗组Hcy、hs-CRP、丙二醛及SOD水平[(18.73±3.62)μmol/L、(6.21±1.06)mg/L、(4.09±0.62)mmol/ml、(55.77±28.83)nU/ml]显著低于前列地尔组[(21.09±3.88)μmol/L、(9.52±1.14)mg/L、(6.01±0.85)mmol/ml、(76.17±30.05)nU/ml]和鼠神经生长因子组[(22.27±4.14)μmol/L、(10.04±1.39)mg/L、(6.14±0.88)mmol/ml、(78.34±29.91)nU/ml]，差异有统计学意义(n P<0.05)。n 结论:前列地尔联合鼠神经生长因子对2型糖尿病神经病变具有较好的缓解作用，联合治疗效果显著优于单独用药效果，值得在临床上推广应用。“,”Objective:To investigate the effects of alprostadil combined with rat nerve growth factor on serum homocysteine(Hcy), high-sensitivity C-reactive protein(hs-CRP)and antioxidant capacity in patients with type 2 diabetic neuropathy.Methods:A retrospective study was performed on 128 patients with type 2 diabetic neuropathy who were admitted from April 2016 to April 2019, 75 males and 53 females, aged(61.13±8.92)years, and the age range was 34 to 78 years.The patients were divided into alprostadil group(n n=37), rat nerve growth factor group(n n=42), and combined treatment group(n n=49)according to different medication methods.Three groups of patients were treated with Toronto peripheral neuropathy score(TCSS )and visual simulation score(VAS); the sensory(SCV)and motor potential(MCV)of the median, tibial, and gastrocnemius nerves were measured using a full-function evoked potentiometer; Hcy, hs-CRP and antioxidant indicators malondialdehyde and superoxide dismutase(SOD)levels.n Results:After treatment, the TCSS and VAS of the combined treatment group[(3.15±0.84)points, (1.35±1.09)points]were significantly lower than those of the alprostadil group[(7.05±1.13)points, (2.13±0.42)points], and the rat nerve Growth factor group[(6.82±1.27)points, (2.05±0.36)points]; SCV in median nerve, tibia nerve, and lower gastrocnemius nerve of the combined treatment group[(49.31±4.15)m/s, (49.15±4.03)m/s, (55.09 4.28)m/s], MCV[(57.84±4.75)m/s, (47.85±4.13)m/s, (48.29±4.35)m/s]were all higher than the alprostadil group[(45.81±3.71)m/s, (45.95±3.88)m/s, (44.07±3.69)m/s, (48.08±4.58)m/s, (39.14±3.04)m/s, (41.04±3.88)m/s]and rat nerve growth factor group[(44.92±3.59)m/s, (48.08±3.92)m/s, (49.27±4.12)m/s, (54.92±4.61)m/s, (43.55±3.92)m/s, (44.27±3.69)m/s]; Hcy, hs-CRP, malondialdehyde, and SOD levels in the combined treatment group[(18.73±3.62)μmol/L, (6.21±1.06)mg/L, (4.09±0.62)mmol/ml, (55.77±28.83)nU/ml]are significantly lower than the alprostadil group[(21.09±3.88)μmol/L, (9.52±1.14)mg/L, 6.01±0.85)mmol/ml, (76.17±30.05)nU/ml]and rat nerve growth factor group[(22.27±4.14)μmol/L, (10.04±1.39)mg/L, (6.14±0.88)mmol/ml, (78.34 ± 29.91)nU/ml], the difference was statistically significant(n P<0.05).n Conclusion:Alprostadil combined with mouse nerve growth factor has a better effect on the remission of type 2 diabetic neuropathy, and the effect of combined treatment is significantly better than that of single drug, which is worthy of reference in clinical practice.